Physician profile
Brian Perry
NPI 1992254486
$2,413.61
in general payments reported to CMS, 2019-2025
12 companies · $679 in 2025
The $679 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $296 · 2023: $726 · 2024: $712 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.61 |
| Education | $107.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $562.28 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $457.12 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $419.64 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $350.38 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.97 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $112.47 | 2024-2025 | Cobenfy |
| Abbvie INC. | $80.45 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.59 | 2022-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $60.04 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $55.36 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $19.42 | 2024 | Uzedy |
| Idorsia Pharmaceuticals US INC | $16.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.